TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Phase 1/2 Completed 37 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab Taiho Pharmaceutical Co., Ltd. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: TAC-101 may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of TAC-101 and to see how well it works in treating patients with advanced hepatocellular carcinoma (liver cancer).

Timeline

Start: 2001-04
Primary completion: 2005-07
Completion: 2005-08

Publications

Results Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008 Dec;134(12):1325-35. doi: 10.1007/s00432-008-0406-2. Epub 2008 May 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMSILAROTENE	Small molecule	20 mg	Oral
Subject	AMSILAROTENE	Small molecule	40 mg	Oral

TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

Summary

Timeline

Publications

Drugs

Indications